Search results for "Inde"

showing 10 items of 7365 documents

Dietary therapy and non-surgical periodontal treatment in obese patients with chronic periodontitis.

2018

Aim The effect of dietary weight loss intervention on periodontal therapy is unknown. Therefore, we aimed to evaluate whether weight loss improves the response of obese subjects to non-surgical periodontal treatment. Materials and methods This interventional study in obese patients was conducted at the University Hospital Dr. Peset (Valencia, Spain). Patients were divided into two groups with and without dietary therapy. All participants received non-surgical periodontal treatment. Periodontal, anthropometric and biochemical parameters were assessed at baseline and 12 weeks. Results A total of 78 patients were re-evaluated after intervention. All periodontal parameters improved in both grou…

medicine.medical_specialtyDiet therapy030209 endocrinology & metabolismSystemic inflammationGastroenterology03 medical and health sciences0302 clinical medicineWeight lossInternal medicinePeriodontal Attachment LossWeight LossMedicineHumansObesityPeriodontitisComplement component 3business.industry030206 dentistryAnthropometrymedicine.diseaseChronic periodontitisObesitySpainChronic PeriodontitisPeriodonticsmedicine.symptomPeriodontal IndexbusinessJournal of clinical periodontology
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Therapeutic dosages of oral or transdermal estradiol did not modify sCD40L levels in postmenopausal women.

2008

The CD40/CD40L system is considered a crucial modulator of the inflammatory process underlying the progression and complication of atheroma plaques. The soluble fraction of CD40L (sCD40L) is a reliable indicator of the CD40/CD40L system. Our purpose was to investigate whether a therapeutic dose of estradiol, by either the oral or the transdermal route, was associated with changes in circulating levels of sCD40L. Forty-seven women completed a 4-week course of treatment with either oral estradiol valerate (2 mg/day, 20 women) or transdermal estradiol (50 microg/day, 27 women). Serum levels of sCD40L were measured by conventional enzyme-linked immunosorbent assay. Oral, but not transdermal est…

medicine.medical_specialtyDoseEndocrinology Diabetes and MetabolismCD40 LigandAdministration OralEnzyme-Linked Immunosorbent AssayPharmacologyAdministration CutaneousFollicle-stimulating hormoneEndocrinologyTherapeutic indexInternal medicinemedicineHumansCD40 AntigensTriglyceridesTransdermalmedicine.diagnostic_testEstradiolbusiness.industryTransdermal routeEstradiol valerateObstetrics and Gynecologymedicine.diseaseAtherosclerosisMenopausePostmenopauseEndocrinologyCholesterolFemaleFollicle Stimulating HormoneLipid profilebusinessmedicine.drugGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Body mass reduction markedly improves muscle performance and body composition in obese females aged 61-75 years: comparison between the effects exert…

2004

OBJECTIVE: To investigate the effectiveness of a body mass reduction programme entailing diet caloric restriction and moderate physical activity with or without supplementary treatment with recombinant (r) GH or steroids to improve body composition and muscle performance in severely obese women aged 61-75 years. METHODS: Twenty women were randomly assigned to one of three groups: body mass reduction alone; body mass reduction plus rGH; body mass reduction plus nandrolone undecanoate. Body composition, isotonic muscle strength and anaerobic power output during jumping were determined before and after the 3-week period. RESULTS: Whatever the experimental group considered, body mass (P<0.01…

medicine.medical_specialtyDoseStrength trainingEndocrinology Diabetes and Metabolismmedicine.disease_causeBody Mass IndexEndocrinologyJumpingInternal medicinemedicineHumansNandroloneTestosteroneIsotonic ContractionObesityInsulin-Like Growth Factor IExerciseAgedNandrolone undecanoatebusiness.industryGeneral MedicineLuteinizing HormoneMiddle Agedmedicine.diseaseCombined Modality TherapyObesityEndocrinologyNandroloneGrowth HormoneBody CompositionFemaleFollicle Stimulating HormonebusinessBody mass indexAnaerobic exercisemedicine.drugEuropean Journal of Endocrinology
researchProduct

Longitudinal Study on Growth and Body Mass Index before and after Diagnosis of Childhood Craniopharyngioma

2004

Abstract We analyzed whether childhood craniopharyngioma predisposes to obesity and growth impairment. Height/length, body mass index (BMI), and hypothalamic involvement were evaluated in 90 patients at standardized ages and time points before, after, and at the time of diagnosis. Relevant decreases in height sd score (SDS) started at 10–12 months of age and persisted until diagnosis of childhood craniopharyngioma. Relevant increases in BMI SDS were detectable between 4 and 5 yr of age. Postoperative BMI SDS (yr 1–6) had a weak positive correlation with BMI SDS at the time of diagnosis. In linear regression analysis, hypothalamic tumor involvement (P < 0.001), ponderal index at birth…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryHypothalamusPituitary neoplasmBiochemistryBody Mass IndexCraniopharyngiomaChild DevelopmentEndocrinologyRisk FactorsInternal medicinemedicineHumansNeoplasm InvasivenessPituitary NeoplasmsLongitudinal StudiesObesityRisk factorGrowth DisordersRetrospective Studiesbusiness.industryBody WeightBiochemistry (medical)Childhood CraniopharyngiomaInfantmedicine.diseaseObesityBody HeightCraniopharyngiomaEndocrinologyEl NiñoMultivariate AnalysisHypothalamic NeoplasmDisease SusceptibilitybusinessBody mass indexThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Anthropometric parameters and permanent remission of comorbidities 10 years after open gastric bypass in a cohort with high prevalence of super-obesi…

2017

Abstract Background and aim Roux-en-Y gastric bypass (RYGB) is an effective treatment for weight loss in patients with morbid obesity. However, few studies have assessed its long-term efficacy in super-obese patients. The study objective was to analyse the long-term effectiveness of RYGB and its effect on improvement of comorbidities after 10 years of follow-up, and to compare the results depending on baseline BMI ( 2 vs ≥50 kg/m 2 ). Patients and methods A retrospective study was conducted in 63 patients referred for RYGB with a 10-year or longer follow-up period. Mean BMI before surgery was 55 kg/m 2 . Results Mean BMI decreased to 38.1 kg/m 2 at 10 years of follow-up. The success rates a…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismGastric bypassGastric Bypass030209 endocrinology & metabolismComorbidityBody Mass Index03 medical and health sciencesPostoperative Complications0302 clinical medicineEndocrinologyWeight lossDiabetes mellitusInternal medicineWeight LossPrevalencemedicinePostoperative Period030212 general & internal medicineDyslipidemiasSleep Apnea ObstructiveNutrition and Dieteticsbusiness.industryRemission Inductionnutritional and metabolic diseasesSleep apneaRetrospective cohort studymedicine.diseaseComorbidityObesity MorbidSurgeryTreatment OutcomeDiabetes Mellitus Type 2SpainHypertensionCohortmedicine.symptombusinessDyslipidemiaFollow-Up StudiesEndocrinología, Diabetes y Nutrición
researchProduct

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 D…

2020

Introduction: Liraglutide has several non-glycemic effects, including those on plasma lipids and lipoproteins, contributing to its cardiovascular benefit; however, the exact underlying mechanisms remain unclear. We investigated a novel anti-atherogenic effect of liraglutide in a real-world prospective study on patients with type 2 diabetes (T2DM). Methods: Sixty-two patients with T2DM (31 men, 31 women; mean age ± standard deviation 61 ± 9 years) naïve to incretin-based therapies were treated with liraglutide (1.2 mg/day) as add-on therapy to metformin (1500–3000 mg/day) for 4 months. Laboratory analyses included the assessment of lipoprotein subclass profile by gel electrophoresis (Lipopri…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismLipoproteinsIncretin030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineCardiovascular risk Carotid intima-media thickness Lipoproteins Liraglutide Small dense low-density lipoproteinsType 2 diabetesInternal medicineDiabetes mellitusInternal MedicinemedicineCarotid intima-media thicknessSmall dense low-density lipoproteinsOriginal ResearchLiraglutidebusiness.industryType 2 diabetesLiraglutidemedicine.diseaseCardiovascular riskMetforminEndocrinologyIntima-media thicknessbusinessBody mass indexLipoproteinmedicine.drug
researchProduct

The assessment of vertebral fractures in elderly women with recent hip fractures: the BREAK Study

2012

This study aimed to evaluate the prevalence of vertebral fractures in elderly women with a recent hip fracture. The burden of vertebral fractures expressed by the Spinal Deformity Index (SDI) is more strictly associated with the trochanteric than the cervical localization of hip fracture and may influence short-term functional outcomes. INTRODUCTION: This study aimed to determine the prevalence and severity of vertebral fractures in elderly women with recent hip fracture and to assess whether the burden of vertebral fractures may be differently associated with trochanteric hip fractures with respect to cervical hip fractures. METHODS: We studied 689 Italian women aged 60 years or over with …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismOsteoporosisDentistryWalkingelderlySeverity of Illness Indexvertebral fracture; hip fracture; elderly; osteoporosis; burdenThoracic VertebraeburdenHip fractureInternal medicinemedicinePrevalenceHumansLife StyleSpinal deformity indexCervical fractureTrochanteric fractureAgedAged 80 and overHip fractureLumbar VertebraeCervical fracturebusiness.industryHip FracturesSettore MED/34 - Medicina Fisica E RiabilitativaMiddle Agedmedicine.diseaseosteoporosisRheumatologyRadiographyItalyOrthopedic surgerycervical fracutre hip fracture spinal deformity index trochanteric fracture vertebral fractureSpinal deformitySpinal FracturesFemaleVertebral fracturebusinessOsteoporotic Fractures
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Clinical factors affecting endometrial receptiveness in oocyte donation cycles.

2008

Objective To provide a summary of the actual knowledge about the clinical factors affecting the oocyte recipient (other than those associated with uterine cavity abnormalities) on the outcome of oocyte donation cycles. Design Review of the literature. Setting Information regarding the association between age, body mass index (BMI), endometrial priming, tobacco consumption, hydrosalpinx, and endometriosis/adenomyosis in oocyte recipients and the results of oocyte donation cycles. Result(s) Recipient age and the presence of hydrosalpinx are clearly associated with a poorer outcome in oocyte donation cycles. The negative impact of tobacco consumption has recently been confirmed. The exact rele…

medicine.medical_specialtyEndometriosisEndometriosisEndometriumBody Mass IndexEndometriumPregnancyMedicineHumansAdenomyosisEmbryo ImplantationHydrosalpinxGynecologyPregnancyOocyte Donationbusiness.industrySmokingAge FactorsPregnancy OutcomeObstetrics and GynecologyFertility Agents FemaleFallopian Tube Diseasesmedicine.diseaseOocytemedicine.anatomical_structureReproductive MedicineFemaleUterine cavitybusinessBody mass indexFertility and sterility
researchProduct